NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations

Author：              

Publisher： Spandidos Publications

ISSN： 1019-6439

Source： International Journal of Oncology, Vol.40, Iss.4, 2012-01, pp. : 1259-1266

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer

By        

International Journal of Oncology, Vol. 43, Iss. 5, 2013-01 ,pp. : 1627-1635

Spandidos Publications

Access to resources Recommend Favorite

NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells

By                    

International Journal of Oncology, Vol. 45, Iss. 3, 2014-01 ,pp. : 1027-1035

Spandidos Publications

Access to resources Recommend Favorite

A novel imidazopyridine PI3K inhibitor with anticancer activity in non-small cell lung cancer cells

By              

Oncology Reports, Vol. 30, Iss. 2, 2013-01 ,pp. : 863-869

Spandidos Publications

Access to resources Recommend Favorite

Intravesical dual PI3K/mTOR complex 1/2 inhibitor NVP-BEZ235 therapy in an orthotopic bladder cancer model

By                

International Journal of Oncology, Vol. 47, Iss. 1, 2015-01 ,pp. : 377-383

Spandidos Publications

Access to resources Recommend Favorite

The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells

By            

Molecular Medicine Reports, Vol. 5, Iss. 2, 2012-01 ,pp. : 503-508

Spandidos Publications

Access to resources Recommend Favorite